| NCT07241390A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | Orforglipron Cardiovascular disease, Chronic kidney disease | Established ASCVD/CKD | Ph 3 | Recruiting | 568 | Aug 2031 | — | |
| ACHIEVE-4A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | Orforglipron Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 358 | Mar 2026 | — | |
| ATTAIN-1A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Orforglipron Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 3 | Active, not recruiting | 138 | Jul 2025 | 1 | |
| ATTAIN-PADEfficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Orforglipron Cardiovascular disease | — | Ph 3 | Recruiting | 138 | Jun 2028 | — | |
| RESTRAIN-SUIA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Orforglipron Obesity / overweight, Urinary Incontinence, Stress | Female | Ph 3 | Recruiting | 137 | Mar 2028 | — | |
| ATTAIN-2A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 136 | Aug 2025 | 1 | |
| ACHIEVE-3A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron, Semaglutide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 131 | Aug 2025 | 1 | |
| NCT06948422A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | Orforglipron Hypertension, Obesity / overweight | BMI ≥25 | Ph 3 | Active, not recruiting | 100 | Sep 2027 | — | |
| NCT06948435A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Orforglipron Hypertension, Obesity / overweight | — | Ph 3 | Active, not recruiting | 99 | Sep 2027 | — | |
| NCT06952530A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | Orforglipron Hypertension, Obesity / overweight | — | Ph 3 | Active, not recruiting | 99 | Sep 2027 | — | |
| ATTAIN-OA PAINA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Orforglipron Obesity / overweight, Osteoarthritis | — | Ph 3 | Recruiting | 95 | Apr 2028 | — | |
| ACHIEVE-1A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 89 | Apr 2025 | 1 | results |
| NCT06972459A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Orforglipron Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| NCT06972472A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| NCT06993792A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Orforglipron Obesity / overweight, Type 2 diabetes | — | Ph 3 | Active, not recruiting | 80 | Aug 2027 | — | |
| ACHIEVE-2A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 74 | Sep 2025 | — | |
| ACHIEVE-5A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 70 | Sep 2025 | — | |
| ATTAIN-OSAA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Orforglipron Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 3 | Active, not recruiting | 66 | Nov 2026 | — | |
| ADVANCEA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Orforglipron Obesity / overweight | Age 6-17 | Ph 3 | Recruiting | 50 | Feb 2027 | — | |
| NCT05048719A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Orforglipron Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 44 | Sep 2022 | 2 | results |
| NCT06672939A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Orforglipron Obesity / overweight | Age 12-17 | Ph 3 | Recruiting | 40 | Dec 2027 | — | |
| ACHIEVE-JA Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Orforglipron Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 40 | Jun 2025 | — | |
| ACHIEVE-RAMA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | Orforglipron Obesity / overweight, Type 2 diabetes | HbA1c ≥7% | Ph 3 | Not yet recruiting | 37 | May 2027 | — | |
| NCT05051579A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities | Orforglipron Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 35 | Aug 2022 | 2 | results |
| NCT06584916A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Orforglipron Obesity / overweight | — | Ph 3 | Completed | 29 | Nov 2025 | 1 | |
| ATTAIN-JA Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Orforglipron Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 16 | Jun 2025 | — | |
| NCT06440980A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight | Orforglipron Healthy volunteers, Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 7 | Jun 2025 | 1 | |
| NCT04426474A Study of LY3502970 in Participants With Type 2 Diabetes | Orforglipron Type 2 diabetes | BMI 18.5-45 | Ph 1 | Completed | 6 | Jul 2021 | — | results |
| NCT05086445A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus | Orforglipron Type 2 diabetes | HbA1c 7-10% | Ph 1 | Completed | 5 | Sep 2022 | — | |
| NCT05882032A Study of LY3502970 in Participants With Impaired and Normal Liver Function | Orforglipron Healthy volunteers, Hepatic impairment | BMI 18.5-40 | Ph 1 | Completed | 4 | Nov 2024 | — | results |
| NCT05936138A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment. | Orforglipron Healthy volunteers, Renal impairment, Type 2 diabetes | BMI 18.5-42 | Ph 1 | Completed | 4 | Apr 2024 | — | |
| NCT06824051A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight | Orforglipron Obesity / overweight | — | Ph 1 | Completed | 4 | Jan 2026 | — | |
| NCT05313802A Study of LY3502970 in Healthy Overweight and Obese Participants | Orforglipron Healthy volunteers, Obesity / overweight | — | Ph 1 | Completed | 3 | Sep 2022 | — | results |
| NCT05841238A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants | Orforglipron Healthy volunteers, Obesity / overweight | Healthy volunteers | Ph 1 | Completed | 3 | Sep 2023 | — | |
| NCT06023095A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities | Orforglipron Obesity / overweight | BMI ≥30 | Ph 1 | Completed | 3 | Jul 2024 | — | |
| NCT06692348A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants | Orforglipron Healthy volunteers | BMI 23-35 | Ph 1 | Completed | 3 | Jun 2025 | — | |
| NCT06186622A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | Orforglipron Healthy volunteers, Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 2 | Jul 2024 | — | results |
| NCT03929744A Study of LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | Healthy volunteers | Ph 1 | Completed | 1 | Nov 2020 | 1 | |
| NCT04680767A Study of LY3502970 in Healthy Male Participants | Orforglipron Healthy volunteers | BMI 18-32 | Ph 1 | Completed | 1 | Jul 2021 | — | results |
| NCT05051566A Multiple Dose Study of LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Apr 2022 | — | results |
| NCT05110794A Multiple-Dose Study of LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Feb 2022 | 1 | results |
| NCT05341089A Study of Two Different Formulations of LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Sep 2022 | — | results |
| NCT05469126A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Nov 2022 | — | results |
| NCT05573230A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Jan 2023 | — | results |
| NCT06085482A Phase I Study of LY3502970 in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Jan 2024 | — | results |
| NCT06704763A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Feb 2025 | — | results |
| NCT06370728A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | Orforglipron Healthy volunteers | BMI 18.5-35 | Ph 1 | Completed | 1 | Jul 2024 | — | |
